medRxiv PreprintsInternational14 October 2026
Cerebrospinal fluid dopa-decarboxylase is a biomarker of dopaminergic dysfunction
This is an official announcement record
Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.
Background. Nigrostriatal dopaminergic dysfunction, a biological anchor of Parkinson's disease (PD), is routinely assessed using single-photon emission computed tomography of the dopamine transporter (DaT-SPECT). Dopa decarboxylase (DDC) in cerebrospinal fluid (CSF) is a promising biomarker of dopaminergic dysfunction, but its association with DaT-SPECT has to be demonstrated. Objectives. To investigate the association of CSF DDC with DaT-SPECT. Methods. We first analysed proteomic and DaT-SPECT data from the Parkinson's Progression Markers Initiative (PPMI), including PD (n=891), prodromal PD
Read the official announcement
Opens www.medrxiv.org
More from medRxiv Preprints
- OSS-DBS v2: Simulation Platform for Biophysical Modelling of Deep Brain Stimulation14 October 2026
- A Growing Burden, a Persistent Gap: Cannabinoid Hyperemesis Syndrome Education and Emergency Department Trends in Michigans Legal Cannabis Market14 October 2026
- Enhanced local synchronization with impaired large-scale recruitment of NREM slow waves in pediatric disorders of arousal14 October 2026
- Bench Testing of an 8 N Slip Resistance Specification for the Handle Shaft Locking Interface of an Articulated Laparoscopic Instrument14 October 2026
- Neurophysiological monitoring of sport related concussion: From diagnosis to return to play14 October 2026
This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program — especially if you are pregnant, nursing, taking medication, or managing a health condition.